BRAF-话题@MedSci

#BRAF#

112篇内容 | 1726人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2186168, encodeId=b58c21861689e, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a> <a href='/topic/show?id=ed621824388' target=_blank style='color:#2F92EE;'>#V600E突变#</a> <a href='/topic/show?id=48df110942b2' target=_blank style='color:#2F92EE;'>#ALK点突变#</a> <a href='/topic/show?id=867c110943c8' target=_blank style='color:#2F92EE;'>#布格替尼#</a>, objectTitle=HIP-ALK重排肺腺癌经治后继发BRAF V600E突变和ALK点突变，最终获益布格替尼, objectType=article, longId=812420, objectId=2ac4812420f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668017232524_4754896.png, objectUrl=/article/show_article.do?id=2ac4812420f4, replyNumber=0, likeNumber=20, createdTime=2024-02-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=2ac4812420f4, moduleTitle=HIP-ALK重排肺腺癌经治后继发BRAF V600E突变和ALK点突变，最终获益布格替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ac4812420f4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184875, encodeId=3fc921848e515, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=大咖谈 | 晚期BRAF突变黑色素瘤的药物治疗策略, objectType=article, longId=810779, objectId=da66810e79b1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=da66810e79b1, replyNumber=0, likeNumber=25, createdTime=2024-01-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=da66810e79b1, moduleTitle=大咖谈 | 晚期BRAF突变黑色素瘤的药物治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da66810e79b1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2172655, encodeId=236c21e26557c, content=<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a> <a href='/topic/show?id=4b0e60250e2' target=_blank style='color:#2F92EE;'>#曲美替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例, objectType=article, longId=803212, objectId=4d44803212b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/senior-doctor-at-workplace-VQC5M89.jpg, objectUrl=/article/show_article.do?id=4d44803212b3, replyNumber=0, likeNumber=36, createdTime=2023-12-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4d44803212b3, moduleTitle=大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d44803212b3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2171140, encodeId=113021e11408c, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a> <a href='/topic/show?id=b279139152c' target=_blank style='color:#2F92EE;'>#PD-1抗体治疗#</a> <a href='/topic/show?id=870d10e88072' target=_blank style='color:#2F92EE;'>#MEKi#</a>, objectTitle=读书报告 | BRAFi和MEKi联合PD-1抗体治疗BRAF 突变型CRC的II期临床研究, objectType=article, longId=802246, objectId=c4de8022463d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medics-and-patient-on-hospital-gurney-at-PMW6NAQ.jpg, objectUrl=/article/show_article.do?id=c4de8022463d, replyNumber=0, likeNumber=39, createdTime=2023-11-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4de8022463d, moduleTitle=读书报告 | BRAFi和MEKi联合PD-1抗体治疗BRAF 突变型CRC的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4de8022463d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2161857, encodeId=de06216185e1e, content=高达50%的<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a>可能是<a href='/topic/show?id=877631e09af' target=_blank style='color:#2F92EE;'>#分子靶向治疗#</a>的潜在受益者。几项规模较小的临床试验显示了二线以上靶向治疗的潜力。比如<a href='/topic/show?id=5ae0e40125' target=_blank style='color:#2F92EE;'>#FGFR2#</a>、<a href='/topic/show?id=f5d71312e50' target=_blank style='color:#2F92EE;'>#NTRK#</a>、<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>、<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>、<a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a>等<a href='/topic/show?id=e6924180936' target=_blank style='color:#2F92EE;'>#基因突变#</a>。以及<a href='/topic/show?id=85cd50561c3' target=_blank style='color:#2F92EE;'>#微卫星不稳定性#</a>MSI的情况，这些相关指标的检测也将会为胆管癌患者的精准治疗打下相应的治疗基础。事实上，其它<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>也是一样的，各个不同的肿瘤都应该按这个思路研究一遍，对于象<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a>，<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，同样如此，梅斯各位会员们，你们如果有兴趣，要尽快研究，这是一个很好的方向，当然，也可以申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a><a href='/topic/show?id=cebd410388c' target=_blank style='color:#2F92EE;'>#国自然基金#</a>, objectTitle=真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！, objectType=article, longId=794442, objectId=b596e944427e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=b596e944427e, replyNumber=0, likeNumber=83, createdTime=2023-10-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b596e944427e, moduleTitle=真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b596e944427e)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1355048, encodeId=2ac7135504875, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, objectType=article, longId=734132, objectId=690de34132b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690de34132b5, replyNumber=0, likeNumber=51, createdTime=2022-08-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690de34132b5, moduleTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690de34132b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355047, encodeId=b160135504ee0, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=53, createdTime=2022-07-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355046, encodeId=892a1355046a2, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, objectType=article, longId=729659, objectId=add1e2965928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add1e2965928, replyNumber=0, likeNumber=56, createdTime=2022-06-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add1e2965928, moduleTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add1e2965928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355045, encodeId=6ac0135504574, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, objectType=article, longId=729558, objectId=3e05e29558cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e05e29558cc, replyNumber=0, likeNumber=67, createdTime=2022-06-16, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e05e29558cc, moduleTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e05e29558cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355044, encodeId=5b60135504446, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, objectType=article, longId=727754, objectId=ef63e277540f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef63e277540f, replyNumber=0, likeNumber=49, createdTime=2022-05-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef63e277540f, moduleTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef63e277540f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355043, encodeId=fe9b135504386, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=54, createdTime=2022-05-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355042, encodeId=5e9b1355042e6, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=53, createdTime=2022-03-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355041, encodeId=4334135504161, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, objectType=article, longId=301463, objectId=dae03014634c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae03014634c, replyNumber=0, likeNumber=0, createdTime=2022-03-24, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae03014634c, moduleTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae03014634c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355040, encodeId=4b4e135504089, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, objectType=article, longId=301132, objectId=c2d23011325d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d23011325d, replyNumber=0, likeNumber=49, createdTime=2022-03-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d23011325d, moduleTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d23011325d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355039, encodeId=5a401355039da, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, objectType=article, longId=299377, objectId=94492993e786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94492993e786, replyNumber=0, likeNumber=43, createdTime=2022-02-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94492993e786, moduleTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94492993e786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355038, encodeId=198f135503848, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, objectType=article, longId=295362, objectId=66af295362ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66af295362ac, replyNumber=0, likeNumber=64, createdTime=2022-02-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66af295362ac, moduleTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66af295362ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355037, encodeId=5550135503e0b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=42, createdTime=2022-01-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355036, encodeId=37db13550364b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效, objectType=article, longId=221246, objectId=2b0d221246c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0d221246c4, replyNumber=0, likeNumber=49, createdTime=2021-11-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0d221246c4, moduleTitle=Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0d221246c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355035, encodeId=1aab1355035ec, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, objectType=article, longId=219570, objectId=1d282195e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d282195e0e7, replyNumber=0, likeNumber=50, createdTime=2021-11-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d282195e0e7, moduleTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d282195e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355034, encodeId=76db1355034ef, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=54, createdTime=2021-10-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #BRAF# #V600E突变# #ALK点突变# #布格替尼#

HIP-ALK重排肺腺癌经治后继发BRAF V600E突变和ALK点突变，最终获益布格替尼

2024-02-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#黑色素瘤# #BRAF#

大咖谈 | 晚期BRAF突变黑色素瘤的药物治疗策略

2024-01-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#EGFR# #BRAF# #曲美替尼# #奥希替尼# #达拉非尼#

大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例

2023-12-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #BRAF# #PD-1抗体治疗# #MEKi#

读书报告 | BRAFi和MEKi联合PD-1抗体治疗BRAF 突变型CRC的II期临床研究

2023-11-26

(审核中...)

前往app查看评论内容

全文收起高达50%的#胆管癌#可能是#分子靶向治疗#的潜在受益者。几项规模较小的临床试验显示了二线以上靶向治疗的潜力。比如#FGFR2#、#NTRK#、#IDH1#、#BRAF#、#HER2#等#基因突变#。以及#微卫星不稳定性#MSI的情况，这些相关指标的检测也将会为胆管癌患者的精准治疗打下相应的治疗基础。事实上，其它#肿瘤#也是一样的，各个不同的肿瘤都应该按这个思路研究一遍，对于象#三阴性乳腺癌#，#小细胞肺癌#，#卵巢癌#，同样如此，梅斯各位会员们，你们如果有兴趣，要尽快研究，这是一个很好的方向，当然，也可以申请#国家自然科学基金##国自然基金#

真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！

2023-10-10发表于上海

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益

2022-08-03

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-10

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效

2022-06-17

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌

2022-06-16

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效

2022-05-26

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-03-26

heli0118 (审核中...)

前往app查看评论内容

#BRAF#

Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响

2022-03-24

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关

2022-03-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效

2022-02-23

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效

2022-02-11

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet Oncol：达拉菲尼联合曲美替尼在BRAFV600E突变阳性胶质瘤中的疗效

2021-11-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理

2021-11-02

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2021-10-17

科室
- - 订阅+
  - 更多科室
工具
服务